Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Other EventsItem 8.01. Other Events.
On December 12, 2016, Akorn, Inc. (the “Company”), announced that the U.S. Food and Drug Administration (FDA) conducted a re-inspection of its Decatur, Illinois manufacturing facility from December 5, 2016 to December 9, 2016, with no Form 483 observations. The re-inspection was conducted to verify the implementation and effectiveness of the Company’s responses to the observations from the June 2016 FDA inspection. A copy of the press release is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. See attached exhibit index.
About Akorn, Inc. (NASDAQ:AKRX)
Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays. The Consumer Health segment is engaged in manufacturing and marketing branded and private-label animal health and OTC products. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. Its OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products. Akorn, Inc. (NASDAQ:AKRX) Recent Trading Information
Akorn, Inc. (NASDAQ:AKRX) closed its last trading session 00.00 at 18.60 with 1,897,884 shares trading hands.